Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 9, 2009, Pages 1413-1419

  Gustavson, Mark D ^a   Bourke Martin, Brian ^a   Reilly, Dylan ^a   Cregger, Melissa ^a   Williams, Christine ^a   Mayotte, Jane ^a   Zerkowski, Maciej ^a   Tedeschi, Greg ^a   Pinard, Robert ^a   Christiansen, Jason ^a  

^a HistoRx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; AUTOMATED QUANTITATIVE ANALYSIS; BREAST CANCER; CALIBRATION; CANCER INVASION; DATA ANALYSIS SOFTWARE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INSTRUMENT; LABORATORY AUTOMATION; PARAMETER; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SCORING SYSTEM; STAINING; STANDARDIZATION; TISSUE MICROARRAY;

ALGORITHMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GUIDELINES AS TOPIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69749092500     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792. (Pubitemid 32222155)
3. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726. (Pubitemid 34111379)
4. Bartlett JM. Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy. Am J Pharmacogenomics. 2005;5:303-315. (Pubitemid 41425608)
5. Hayes DF, Picard MH. Heart of darkness: the downside of trastuzumab. J Clin Oncol. 2006;24:4056-4058.
6. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
7. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032-3038.
8. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854. (Pubitemid 34705057)
9. Hameed O, Adams AL, Baker AC et al. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. Am J Clin Pathol. 2008;130:425-427.
10. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8: 1323-1327. (Pubitemid 35373567)
11. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005;97:1808-1815. (Pubitemid 43033901)
12. Berger AJ, Davis DW, Tellez C, et al. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005;65:11185-11192. (Pubitemid 41713390)
13. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome 31. Cancer Res. 2003;63:1445-1448.
14. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res. 2006;66: 5487-5494. (Pubitemid 43844977)
15. Dolled-Filhart M, Ryden L, Cregger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 2006;12:6459-6468. (Pubitemid 44799719)
16. Giltnane JM, Ryden L, Cregger M, Bendahl PO, Jirstrom K, Rimm DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol. 2007;25:3007-3014. (Pubitemid 47218046)
17. Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol. 2007;25:5418-5425. (Pubitemid 350232218)
18. Pozner-Moulis S, Pappas DJ, Rimm DL. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res. 2006;66: 7976-7982. (Pubitemid 44299161)
19. Psyrri A, Kassar M, Yu Z, et al. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res. 2005;11:8637-8643. (Pubitemid 43005911)
20. Giltnane JM, Molinaro A, Cheng H, et al. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med. 2008;132:1635-1647.
21. Gustavson MD, Bourke-Martin D, Reilly DM, et al. Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using automated quantitative analysis. Appl Immunohistochem Mol Morphol. 2009;17(4):329-337.
22. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization 9. Clin Cancer Res. 2004;10:7252-7259. (Pubitemid 39487712)
23. Raeside DE. Monte Carlo principles and applications. Phys Med Biol. 1976;21:181-197.
24. Butler JE. Enzyme-linked immunosorbent assay. J Immunoassay. 2000;21: 165-209.
25. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17: 1474-1481.
26. Hede K. Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst. 2008;100:836-837, 844.